About Us

Synapto is an early stage biotech company revolutionizing Alzheimer's diagnosis through portable EEG and Machine Learning.


Why it's Important?

Alzheimer's is the 6th leading cause of death in the United States, costing the nation close to $259 billion dollars annually. It can take a doctor upto 2 years to diagnose Alzheimer's after clinical symptoms are presented, making early diagnosis a great challenge. Our innovative device moves away from costly neuroimaging diagnostic techniques and qualitative methods of diagnosis to a more robust, affordable, and objective measure of analysis, a portable Electroencephalogram (EEG).

How it Works

The device works by analyzing a patient's brainwave by using a variety of mathematical analyses and compares it to known healthy and Alzheimer's brainwave biomarkers. Using machine learning characterization, the algorithm can then decide, to a certain level of confidence whether the new brainwave belongs to an Alzheimer's patient or a healthy control patient.

Physical Device

A portable Electroencephalogram records highly sensitive electrical signals in the brain, which can then be analyzed using our mathematical biomarkers and analyses. This recording then allows the models to predict the severity and progression of the disease. Synapto is utilizing portable EEG from OpenBCI, making our device unique in that it is smaller, affordable, and more effective than current diagnostic measures.


Synapto in the Media

What They Say About Us.

  • Synapto’s project serves as a prime example of how tomorrow’s bioengineers are working today to find solutions to some of the most significant health challenges our society faces

    Author image
    John Fisher Fischell Family Distinguished Professor and BIOE chair
  • This represents a monumental achievement, not simply for the engineering community, but for the wider world of human health research.

    Author image
    Darryll J. Pines Dean of the Clark School and Nariman Farvardin Professor.
  • I think the device is unique and will prove to be the first line of testing in the future for detection of Alzheimer disease.

    Author image
    Roopal Karia, MD Clinical Professor in Neurology

Meet the Team


Dhruv Patel


Christopher Look


David Boegner
Lead Systems Engineer


Megha Guggari
Lead Software Engineer


Anoop Patel
Lead R&D Engineer